From Discovery to Validation 
Today, the work sits between discovery and 
commercialization. 
“This research has reached the validation phase,” Rustgi 
says. 
The team has done most of the lab work and allergy test­
ing. A few more steps will show whether the peanuts are 
ready for release.  
He says the team needs additional human cell line–based 
assays are to confirm reduced immunogenicity. 
 “We must evaluate these genotypes through feeding 
trials using humanized rodent models and through human 
skin-prick testing, followed by agronomic evaluations and 
quality assessments,” he explains. 
Those milestones will signal whether reduced-allergen 
peanuts can move from experimental lines into production 
systems. 
Rustgi sees clear commercial relevance emerging as vali­
dation continues. 
“These materials will serve as a premium product suit­
able for use in public spaces such as schools and airlines,” he 
says. “They reduce the risk of triggering an immune reaction 
and can also serve as an affordable source of oral immuno­
therapy.” 
Existing infrastructure supports that transition. 
Clemson University graduate student Hrishikesh Ingole works with peanut embryogenic calli as part of a research program using genome 
editing to target genes associated with major peanut allergens. 
PHOTO: CLEMSON UNIVERSITY
58  / SEEDWORLD.COM  DECEMBER 2026
Graduate student Hrishikesh Ingole maintains advanced reduced-
immunogenicity peanut lines. The Clemson team is moving 
promising material through additional immunological, agronomic 
and quality testing as it works toward potential release. 
PHOTO: CLEMSON UNIVERSITY
“These genotypes can be processed using the same shell­
ing and processing facilities currently employed to separate 
high-oleic peanuts from regular peanuts,” Rustgi says. “The 
existing production stream used for peanut-free products 
can also be leveraged.” 

View this content as a flipbook by clicking here.